Understanding evidence

Know which question each test answers.

A result is useful when you know what was measured, what it can miss, and what decision it can change.

Tumor biology and inherited risk are different

My tumor has deficient mismatch repair, or dMMR. This finding concerns a system that repairs errors in DNA. It is relevant to treatment discussions, but it does not by itself establish an inherited cancer syndrome.

Tumor testing examines features of the cancer. Germline testing investigates inherited changes, usually using blood or saliva. Tumor results can prompt genetic evaluation; they do not replace it. [1]

A biomarker is not a complete treatment plan

A biomarker can make a therapy worth considering. The cancer type, stage, prior treatment, and treatment setting still matter. A matching biomarker does not guarantee that the therapy will work. [2]

For me, the important question is not only whether dMMR tumors respond to immunotherapy. It is what evidence supports a particular approach after surgery for this tumor type.

ctDNA has a different job

Circulating tumor DNA is tumor-derived DNA measured in the blood. Some assays look for mutations without first designing a patient-specific tumor panel. Others use a person’s tumor to build a tailored test for monitoring.

Research in appendiceal adenocarcinoma has found lower blood ctDNA detection than in colorectal cancer in a mutation-profiling setting. That is a reason to ask about the limits of a negative result. It is not a sensitivity estimate for every assay, disease stage, or postoperative situation. [3]

A negative result has limits

“Not detected” is a test result. Ask the team how much it lowers concern in your specific setting and how it fits with imaging, pathology, and follow-up. It is not a stand-alone reason to omit treatment.

Before ordering, ask what changes

  • What question will this test answer?
  • Does it need tissue, blood, or both?
  • How should a positive, negative, or inconclusive result affect the plan?
  • What evidence supports that use in my cancer type?
  • Will the result arrive in time to inform the decision?

More testing is not automatically better. A useful test reduces uncertainty that matters for care, with its limitations made explicit.

Sources & scope

  1. Genetic testing for inherited cancer risk ↗National Cancer Institute. The distinction between tumor findings and inherited changes.
  2. Biomarker testing for cancer treatment ↗National Cancer Institute. What tumor testing can and cannot tell you.
  3. The Landscape of ctDNA in Appendiceal Adenocarcinoma ↗Clinical Cancer Research · institutional publication record. Blood-based mutation profiling. Its detection rates are not the sensitivity of every tumor-informed residual-disease assay.

Research links checked November 2026. Patient-written interpretation; not a clinical review.

Keep readingLet agents do the information work